Table 1 Patient characteristics in the study
Characteristic | Overall N = 4,040 | Training N = 2,828 | Validation set N = 1,212 | p-value |
|---|---|---|---|---|
Age, n (%) | 0.11 | |||
< 59 | 1,980 (49.0%) | 1,363 (48.2%) | 617 (50.9%) | |
>=59 | 2,060 (51.0%) | 1,465 (51.8%) | 595 (49.1%) | |
Race, n (%) | 0.24 | |||
Black | 490 (12.1%) | 352 (12.4%) | 138 (11.4%) | |
Other | 495 (12.3%) | 332 (11.7%) | 163 (13.4%) | |
White | 3,055 (75.6%) | 2,144 (75.8%) | 911 (75.2%) | |
Radiation, n (%) | 0.033 | |||
No/Unknown | 2,596 (64.3%) | 1,847 (65.3%) | 749 (61.8%) | |
Yes | 1,444 (35.7%) | 981 (34.7%) | 463 (38.2%) | |
Chemotherapy, n (%) | 0.18 | |||
No/Unknown | 1,129 (27.9%) | 808 (28.6%) | 321 (26.5%) | |
Yes | 2,911 (72.1%) | 2,020 (71.4%) | 891 (73.5%) | |
T stage, n (%) | 0.57 | |||
T1 | 1,424 (35.2%) | 1,008 (35.6%) | 416 (34.3%) | |
T2 | 1,974 (48.9%) | 1,385 (49.0%) | 589 (48.6%) | |
T3 | 459 (11.4%) | 310 (11.0%) | 149 (12.3%) | |
T4 | 183 (4.5%) | 125 (4.4%) | 58 (4.8%) | |
N stage, n (%) | 0.007 | |||
N0 | 1,213 (30.0%) | 856 (30.3%) | 357 (29.5%) | |
N1 | 1,561 (38.6%) | 1,119 (39.6%) | 442 (36.5%) | |
N2 | 769 (19.0%) | 499 (17.6%) | 270 (22.3%) | |
N3 | 497 (12.3%) | 354 (12.5%) | 143 (11.8%) | |
ER, n (%) | 0.55 | |||
Negative | 1,361 (33.7%) | 961 (34.0%) | 400 (33.0%) | |
Positive | 2,679 (66.3%) | 1,867 (66.0%) | 812 (67.0%) | |
PR, n (%) | 0.11 | |||
Negative | 2,054 (50.8%) | 1,461 (51.7%) | 593 (48.9%) | |
Positive | 1,986 (49.2%) | 1,367 (48.3%) | 619 (51.1%) | |
Grade, n (%) | 0.32 | |||
I | 147 (3.6%) | 94 (3.3%) | 53 (4.4%) | |
II | 1,243 (30.8%) | 871 (30.8%) | 372 (30.7%) | |
III | 2,643 (65.4%) | 1,859 (65.7%) | 784 (64.7%) | |
IV | 7 (0.2%) | 4 (0.1%) | 3 (0.2%) |